Note 7 - Segment Information (Tables)

9 Months Ended

Sep. 30, 2012

Schedule of Segment Reporting Information, by Segment [Table Text Block]

	Three months ended September 30, 2012
	Medical Business			Extraction Business			Total

Operating revenue	$	815,566		$	250,563		$	1,066,129
Cost of revenue		(312,231	)		(81,756	)		(393,987	)

Gross profit	$	503,335		$	168,807		$	672,142

Depreciation and amortization	$	331,491		$	69,371		$	400,862
Net income		310,770			27,130			337,900
Expenditure for long-lived assets	$	-		$	-		$	-

	Nine months ended September 30, 2012
	Medical Business			Extraction Business			Total

Operating revenue	$	2,465,957		$	712,966		$	3,178,923
Cost of revenue		(584,928	)		(202,434	)		(787,362	)

Gross profit	$	1,881,029		$	510,532		$	2,391,561

Depreciation and amortization	$	642,741		$	208,589		$	851,330
Net income		1,201,418			20,682			1,222,100
Expenditure for long-lived assets	$	21,342		$	1,489		$	22,831

	Three months ended September 30, 2011
	Medical Business			Extraction Business			Total

Operating revenue, net	$	989,854		$	182,269		$	1,172,123
Cost of revenue		(158,580	)		(29,868	)		(188,448	)

Gross profit	$	831,274		$	152,401		$	983,675

Depreciation and amortization	$	153,605		$	58,668		$	212,273
Net income		577,255			74,349			651,604
Expenditure for long-lived assets	$	1,564,983		$	274,427		$	1,839,410

	Nine months ended September 30, 2011
	Medical Business			Extraction Business			Total

Operating revenue, net	$	2,652,218		$	675,760		$	3,327,978
Cost of revenue		(474,498	)		(120,591	)		(595,089	)

Gross profit	$	2,177,720		$	555,169		$	2,732,889

Depreciation and amortization	$	453,822		$	164,388		$	618,210
Net income		1,457,570			281,712			1,739,282
Expenditure for long-lived assets	$	1,564,983		$	274,427		$	1,839,410

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References+ Details

GFR PHARMACEUTICALS INC 10-Q